psilocybin low-dose (MLS101)
/ MycoMedica
- LARVOL DELTA
Home
Next
Prev
1 to 8
Of
8
Go to page
1
September 03, 2025
A Study Assessing Brain Activity, Safety, Tolerability, and Pharmacokinetics Following Multiple Doses of MLS101 (Psilocybin) in Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=20 | Recruiting | Sponsor: MycoMedica Life Sciences PBC | Not yet recruiting ➔ Recruiting
Enrollment open
July 03, 2025
A Study Assessing Brain Activity, Safety, Tolerability, and Pharmacokinetics Following Multiple Doses of MLS101 (Psilocybin) in Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=20 | Not yet recruiting | Sponsor: MycoMedica Life Sciences PBC
New P1 trial
June 12, 2025
24-MLS101-102: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=16 | Completed | Sponsor: MycoMedica Life Sciences PBC | Active, not recruiting ➔ Completed | N=24 ➔ 16
Enrollment change • Trial completion
April 11, 2025
24-MLS101-102: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=24 | Active, not recruiting | Sponsor: MycoMedica Life Sciences PBC | Recruiting ➔ Active, not recruiting
Enrollment closed
December 12, 2024
24-MLS101-102: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=24 | Recruiting | Sponsor: MycoMedica Life Sciences PBC | Not yet recruiting ➔ Recruiting
Enrollment open
October 16, 2024
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=24 | Not yet recruiting | Sponsor: MycoMedica Life Sciences PBC
New P1 trial
October 09, 2024
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLS101 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=24 | Completed | Sponsor: MycoMedica Life Sciences PBC | Recruiting ➔ Completed
Trial completion
May 06, 2024
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLS101 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=24 | Recruiting | Sponsor: MycoMedica Life Sciences PBC | N=80 ➔ 24
Enrollment change
1 to 8
Of
8
Go to page
1